Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

MDT Management of Borderline Resectable Early-Stage NSCLC and Delayed Surgery After Neoadjuvant IO

July 22nd 2025

Panelists discuss how borderline resectable patients can be made resectable through neoadjuvant chemoimmunotherapy when surgeons have clear, objective goals for what they aim to achieve rather than vague hopes to make surgery “less scary.”

First-Line Osimertinib Plus Chemo Boosts OS in EGFR+ NSCLC

July 21st 2025

Osimertinib plus chemotherapy improved overall survival in the first-line treatment of advanced non–small cell lung cancer harboring EGFR mutations.

Five Under 5: Top Oncology Videos for the Week of 7/13

July 20th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC

July 18th 2025

Sandip P. Patel, MD, discusses targeted therapy combination regimens in EGFR-mutated NSCLC.

Perioperative Nivolumab in Resectable NSCLC: Updated Data From CheckMate-77T

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.

How Immunotherapy Is Affecting Perioperative Treatment Decisions in Early-Stage NSCLC

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.

Dr Singhi on the Rationale for Evaluating Lurbinectedin Plus Atezolizumab in ES-SCLC

July 15th 2025

Eric K. Singhi, MD, explains the rationale for evaluating lurbinectedin plus atezolizumab as maintenance therapy after chemotherapy in ES-SCLC.

Expert Perspectives in Challenging Situations: Progression After Neoadjuvant Chemoimmunotherapy

July 15th 2025

Panelists discuss how to manage patients who cannot proceed to surgery after neoadjuvant chemoimmunotherapy by pivoting to definitive concurrent chemoradiation with reduced-dose chemotherapy, while emphasizing the need to distinguish true progression from inflammatory changes.

ASCO 2025 Real-World Data on Neoadjuvant Therapy in Stage II to III NSCLC: Surgical Outcomes and Clinical Implications

July 15th 2025

Panelists discuss how real-world data from the Flatiron Health database revealed that surgical completion rates after neoadjuvant therapy are lower in community practice (65%) compared with clinical trials, particularly for patients with poor performance status or more advanced stage disease.

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Lurbinectedin + Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Results of the Phase 3 IMforte Trial

July 11th 2025

The Phase 3 IMforte trial demonstrated that maintenance therapy with lurbinectedin plus atezolizumab was well tolerated and explored a novel approach to extending disease control following first-line treatment in patients with extensive-stage small cell lung cancer.

Dr Puri on Future Research Directions in SCLC

July 9th 2025

Sonam Puri, MD, discusses future research directions and ongoing developments in small cell lung cancer.

Addressing the Most Critical Treatment Questions in EGFR-mutant Advanced NSCLC

July 8th 2025

On May 31, 2025, a select group of US medical and thoracic oncologists from academic and cancer specialty institutions participated in a workshop held in conjunction with the 2025 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. The participants discussed current and emerging therapeutic strategies in treating patients with EGFR-mutant (EGFRm), advanced non–small cell lung cancer (NSCLC). The session was moderated by Helena Yu, MD, who led discussions on managing the balance between improved efficacy outcomes and increased toxicity with combination therapies, and sequencing strategies for first-line and subsequent treatments.

Updates from ASCO 2025 in Advanced Non‒Small Cell Lung Cancer

July 8th 2025

On June 1, 2025, OncLive® convened a group of early career medical oncologists specializing in thoracic malignancies to discuss pivotal abstracts from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO 2025). The session was moderated by Eric K. Singhi, MD, with faculty providing real-world perspectives on emerging therapies, treatment sequencing challenges, and evolving biomarker strategies. The discussion centered on antibody-drug conjugates (ADCs), targeted therapies for oncogene-driven NSCLC, perioperative treatment approaches, and novel diagnostic tools.

Surgical Perspectives: Who Are the Best Candidates for Neoadjuvant Chemoimmunotherapy?

July 8th 2025

Panelists discuss how surgeons evaluate candidates for neoadjuvant chemoimmunotherapy by emphasizing that all patients with stage II and III disease should be considered regardless of PD-L1 or mutation status, while highlighting the importance of multidisciplinary collaboration in treatment decisions.

CheckMate 77T: Updated Survival and Biomarker Insights Shaping Early-Stage NSCLC Care

July 8th 2025

Panelists discuss how the CheckMate 77T perioperative trial updates showed that even patients receiving fewer than 4 cycles of neoadjuvant therapy still benefited, and circulating tumor DNA (ctDNA) clearance serves as an independent biomarker for predicting outcomes regardless of pathologic response status.

Dr Azenkot on Dupilumab Plus Cemiplimab in Early-Stage, Resectable NSCLC

July 7th 2025

Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.

Dr Jeon on Research Presented at an OncLive Lung Cancer Fellows Forum

July 7th 2025

Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.

FDA Approves Oncomine Dx Express Test for Tumor Profiling and as Companion Diagnostic for Sunvozertinib in NSCLC

July 7th 2025

The FDA approved the Oncomine Dx Express Test for tumor profiling and as a companion diagnostic for sunvozertinib in non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.